Cookies on CABI

Like most websites we use cookies. This is to ensure that we give you the best experience possible.

Continuing to use www.cabi.org means you agree to our use of cookies. If you would like to, you can learn more about the cookies we use.

Search this site
Sign up for the CABI e-zine Newsletter
Improving lives by solving problems in agriculture and the environment

Extract supply and screening

Over 90% of our strains are unique; we offer novel, diverse and authenticated organisms. We also have access to thousands more organisms through our links with culture collections and Biological Resource Centres around the world.

We can…

  • - select organisms with properties that meet your needs

  • - offer a molecular approach to help target potential leads

  • - provide cultures and extract libraries for screening programmes

  • - screen for new sources of fatty acids, enzymes, and antimicrobials

  • - manipulate organisms to enhance their potential and expose unique metabolic properties

  • - provide extensive information on microbes through our abstract database of over 5 million records

Our team includes mycologists, molecular biologists, bacteriologists, ecologists and systematists. As an intergovernmental not-for-profit organisation we work within the terms of the Convention on Biological Diversity (CBD), making us an ethical partner for bio-industries.

Through partnering with CABI, we can supply your organization with thousands of targeted strains or extracts from our collection. By screening our microorganisms for products, your scientists may be able to develop new sources of vitamins or discover drugs for improving health and combating diseases such MRSA and cancers.

Some of our current partnerships include:

British Antarctic Survey (BAS), whose collection has been taken into CABI’s care. We are also joining forces to explore these microorganisms for natural products.

PharmaLinks, which brings together the scientific and clinical expertise of the University of Glasgow and the University of Strathclyde. Pharmalinks are screening a targeted selection of our microorganisms and have a strong track record in providing industry with a wealth of new ideas for therapeutic targets, drug candidates and drug delivery.

Royal Botanic Gardens, Kew, who are chemically fingerprinting and screening a selection of our fungal endophyte extracts against insects and selected fungi and bacteria.

Royal Holloway, University of London, who possess specialised equipment and expertise to help with the biochemical characterisation and analysis of our microorganisms and extracts.

*New venture* Surrey Biotech is a new biotechnology venture formed by CABI and Royal Holloway, University of London. The aim is to identify new classes of antibiotics for clinical use against newly emerging and known pathogens that are resistant to existing antimicrobials. Funding is currently being sought.